Implementation of a schizophrenia practice guideline: Clinical results

Journal of Clinical Psychiatry

Volumn 69, Issue 8, 2008, Pages 1299-1306

  Weinmann, Stefan ^a   Hoerger, Susanne ^a   Erath, Monika ^a   Kilian, Reinhold ^a   Gaebel, Wolfgang ^b   Becker, Thomas ^a  

^a UNIVERSITY OF ULM   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENPERIDOL; CARBAMAZEPINE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LITHIUM; LITHIUM CARBONATE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG SUBSTITUTION; EVIDENCE BASED MEDICINE; FEMALE; GERMANY; HEALTH PROGRAM; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH CARE; MONOTHERAPY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIC DEPARTMENT; QUALITY CIRCLE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 49649085334     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0815     Document Type: Article

References (27)

1. Lehman AF. Treatment guidelines: caveat emptor! [editorial] J Ment Health 2006;15:129-133
2. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004 Feb;8(6):iii-iv, 1-72
3. Weinmann S, Koesters M, Becker T. Effects of implementation of psychiatric guidelines on provider performance and patient outcomes: systematic review. Acta Psychiatr Scand 2007;115:420-433
4. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety, and cost outcomes of CATIE and other trials [electronic CME activity]. J Clin Psychiatry 2007 Feb;68(2):e04
5. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaideligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004 Oct;65(10):1377-1388
6. Centorrino F, Eakin M, Bahk WM, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 2002 Nov;159(11):1932-1935
7. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-329
8. Gaebel W, Falkai P, Weinmann S, et al. Behandlungsleitlinie Schizophrenie. Band 1 Praxisleitlinien in Psychiatrie und Psychotherapie [Practice Guideline Schizophrenia, vol. 1: Practice Guidelines in Psychiatry and Psychotherapy of the German Society of Psychiatry, Psychotherapy and Nervous Disease]. Darmstadt, Germany: Steinkopff; 2006
9. Kay SR. Positive and Negative Syndromes in Schizophrenia. New York, NY: Brunner and Mazel; 1991
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
11. Hamann J, Cohen R, Leucht S, et al. Do patients with schizophrenia wish to be involved in decisions about their medical treatment? Am J Psychiatry 2005;162:2382-2384
12. Lieberman JA, Stroup ST, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
13. Burton SC. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. J Psychiatr Pract 2005;11:369-378
14. Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull 2002;28:105-109
15. Carnahan RM, Lund BC, Perry PJ, et al. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand 2006;113:135-141
16. Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition. Am J Psychiatry 2004;161:1-56
17. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004 Apr;65(4):500-508
18. Trivedi MH, Fava M, Marangell LB, et al. Use of treatment algorithms for depression [CME commentary]. J Clin Psychiatry 2006 Sep;67(9):1458-1465
19. Suzuki T, Uchida H, Tanaka KF, et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 2004;7:133-142
20. Dickey B, Normand SL, Eisen S, et al. Associations between adherence to guidelines for antipsychotic dose and health status, side effects, and patient care experiences. Med Care 2006;44:827-834
21. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20-38
22. Bauer MS. A review of quantitative studies of adherence to mental health clinical practice guidelines. Harv Rev Psychiatry 2002;10:138-153
23. Hermann RC, Finnerty M, Provost S, et al. Process measures for the assessment and improvement of quality of care for schizophrenia. Schizophr Bull 2002;28:95-104
24. Dennehy EB, Suppes T, Rush AJ, et al. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? results from the Texas Medication Algorithm Project. Psychol Med 2005 Dec;35(12):1695-1706
25. Grimshaw J, Campbell M, Eccles M, et al. Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Fam Pract 2000 Feb;17(suppl 1):S11-S16
26. Foster M. Propensity score matching: an illustrative analysis of dose response. Med Care 2003;41:1183-1192
27. Morton V, Torgerson DJ. Regression to the mean: treatment effect without the intervention. J Eval Clin Pract 2005;11:59-65